汇宇制药：预计2025年度实现归属于母公司所有者的净利润为亏损2900万元至2400万元

Group 1 - The core viewpoint of the article indicates that Huiyu Pharmaceutical expects a significant net loss for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-on-year decline of 108.91% to 107.38% [1] - The primary reason for this performance change is attributed to the fair value loss of 173 million yuan due to fluctuations in the stock price of its invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the HKEX 18A listing standard [1]